|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5266 USD | -24.11% |
|
-.--% | - |
| 01/07/25 | Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO | CI |
| 01/07/25 | Oncternal Therapeutics, Inc. Announces Management Changes | CI |
| Market Cap | 1.56M 1.37M 1.26M 1.18M 2.21M 147M 2.26M 15.14M 5.86M 72.66M 5.85M 5.72M 252M | P/E 2022 |
-1.19x | P/E 2023 | -0.8x |
|---|---|---|---|---|---|
| Enterprise Value | -32.38M -28.39M -26.17M -24.5M -45.94M -3.05B -46.89M -315M -122M -1.51B -122M -119M -5.23B | EV / Sales 2022 |
-4.9x | EV / Sales 2023 | -2.95x |
| Free-Float |
90.77% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | -24.11% |
| 3 years | 0.53 |  | 13.14 |
| 5 years | 0.53 | | 105.4 |
| 10 years | 0.53 | | 211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Vincent
DFI | Director of Finance/CFO | 63 | 01/04/2017 |
Yisrael Katz
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2023 |
Rajesh Krishnan
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Director | Title | Age | Since |
|---|---|---|---|
David Hale
CHM | Chairman | 77 | 01/12/2018 |
Dan Kisner
BRD | Director/Board Member | 79 | 07/06/2019 |
Rosemary Mazanet
BRD | Director/Board Member | 70 | 27/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 20/06/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/06/24 | Free | Director | 2,200 | 0.0743% | ||
| 20/06/24 | Free | Director | 2,200 | 0.0743% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -24.11% | -.--% | -.--% | -92.44% | 1.56M | |
| -0.48% | +7.20% | -5.08% | +2.45% | 46.2B | |
| +2.19% | +11.71% | +385.81% | +632.13% | 38.71B | |
| +2.53% | +13.93% | +20.85% | -10.61% | 31.9B | |
| +1.65% | +3.61% | +9.98% | +55.42% | 31.12B | |
| -4.16% | -2.58% | +8.74% | +15.22% | 23.77B | |
| -0.32% | +12.96% | - | - | 16.2B | |
| +1.37% | +14.53% | +71.80% | +134.14% | 15.05B | |
| +1.00% | +10.30% | +13.31% | +22.84% | 13.74B | |
| +3.63% | +9.53% | +104.07% | +107.62% | 13.42B | |
| Average | -1.67% | +5.64% | +67.72% | +96.31% | 23.01B | |
| Weighted average by Cap. | +0.75% | +8.71% | +86.68% | +140.74% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 1.49M 1.31M 1.2M 1.13M 2.11M 141M 2.16M 14.47M 5.6M 69.47M 5.59M 5.47M 241M | 785K 688K 634K 594K 1.11M 74.05M 1.14M 7.63M 2.95M 36.6M 2.95M 2.88M 127M |
| Net income | -44.17M -38.73M -35.7M -33.42M -62.67M -4.17B -63.97M -429M -166M -2.06B -166M -162M -7.14B | -39.48M -34.62M -31.91M -29.87M -56.01M -3.72B -57.18M -384M -148M -1.84B -148M -145M -6.38B |
| Net Debt | -63.64M -55.8M -51.43M -48.15M -90.29M -6B -92.17M -618M -239M -2.97B -239M -234M -10.29B | -33.94M -29.76M -27.43M -25.68M -48.15M -3.2B -49.15M -330M -128M -1.58B -127M -125M -5.49B |
Employees
29
- Stock Market
- Stocks
- ONCT Stock
Select your edition
All financial news and data tailored to specific country editions
